{
  "docId": "019de077-0ff3-70e8-97e9-f8df18ead978",
  "docSlug": "2f90f1dc6d9440d196c6f2643a698403",
  "documentTitle": "OmniAb | Results Presentation Deck | 24 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 24,
  "prevPage": 23,
  "nextPage": null,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "The table uses a Gantt-style visualization to show the development status of various drug programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0ff3-70e8-97e9-f8df18ead978/24",
  "deckHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978",
  "deckJsonHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978.json",
  "deckAnchorHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. Indicates program with fully paid license from OMT, inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. On October 31, 2023 Amgen announced plans to discontinue Phase 1 study of AMG 340 in mCRPC.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c535d98b-4e1f-4845-8f8c-df777d3aea87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.04,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Programs shown in Green: New clinical entrants in 2023. Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020; OmniAb 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71766ed6-692d-4c27-b40a-2a8df5f1517e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.78,
        "w": 0.92,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "table",
      "text": "Pipeline table with columns: Partner, Program, Source Animal, Therapy Area, Target, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e756e735-7031-46fd-ae43-1ab9e9f2bbd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 12/31/2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e218e92-dbba-4101-8285-1418a7bfee66",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "05abde37-e56e-4fc7-80b2-6f8fbd30edfe",
      "evidence": "The table uses horizontal bars to represent the development phase of each program.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}